Viking Therapeutics Stock Plunges on Clinical Trial Concerns

Viking Therapeutics is experiencing the downside of its ambitious growth strategy. Recent clinical developments have tempered investor enthusiasm for the biotech firm, sending shares downward despite previous monthly gains. The primary concern stems from high discontinuation rates observed in trials for the company’s oral weight loss medication.

Financial Strain Intensifies as R&D Costs Soar

The company’s latest quarterly report reveals significant financial pressure. During the second quarter of 2025, research and development expenditures surged to $60.2 million—more than double the $23.8 million recorded during the same period last year.

This explosive cost growth has dramatically impacted the bottom line. Viking’s net loss widened substantially to $65.6 million, compared to $22.3 million in the prior year period. While the company maintains solid cash reserves, its aggressive pipeline development strategy is clearly taking a financial toll.

Oral Formulation Shows Efficacy But Raises Safety Questions

The company’s promising weight loss candidate VK2735 presents a complex picture. In Phase 2 trials, the oral medication successfully met all primary and secondary endpoints, achieving average weight reduction of up to 12.2% after 13 weeks.

Should investors sell immediately? Or is it worth buying Viking Therapeutics?

However, significant challenges emerged beneath the surface efficacy data. High dropout rates due to gastrointestinal side effects, including nausea and vomiting, triggered a stock decline when full results were announced in August. The tolerability profile of the oral formulation has become the project’s critical weakness.

Alternative Delivery Methods Offer Path Forward

Investors are finding optimism in the injectable version of the same compound. The subcutaneous formulation of VK2735 has progressed to the large-scale Phase 3 VANQUISH trial, having previously demonstrated weight reduction of up to 14.7% in Phase 2 studies.

Beyond this program, Viking continues to advance additional obesity treatments. The company is preparing to submit another obesity program—an amylin agonist—to the FDA in the fourth quarter of 2025. Despite mounting expenses, the company’s development pipeline remains robust with multiple ongoing initiatives.